вторник, 21 февраля 2017 г.

Why GlaxoSmithKline's 2017 Guidance Is Conservative

Why GlaxoSmithKline's 2017 Guidance Is Conservative


Assuming that Advair will face competition from a substitutable generic in the US by mid-2017, GSK guided for flat to a slight decline in Core EPS at constant exchange rates. The stock is trading at a discount to five years average historical P/E vs. peers and some potential source of earnings upside is expected in 2017.



from Biotech News